Patent

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

Retrieved on: 
Tuesday, February 27, 2024

Launched OGSIVEO in the U.S. and achieved net product revenue of $5.4 million in the first partial quarter of the launch.

Key Points: 
  • Launched OGSIVEO in the U.S. and achieved net product revenue of $5.4 million in the first partial quarter of the launch.
  • Presented additional patient-reported outcome data from the Phase 3 DeFi trial at the 2023 Connective Tissue Oncology Society Annual Meeting.
  • Revenues: OGSIVEO net product revenues were $5.4 million in the fourth quarter of 2023, the first partial quarter of the U.S. launch.
  • Cash Position: Cash, cash equivalents and marketable securities were $662.6 million as of December 31, 2023.

Rival Further Simplifies Talent Acquisition with AI Innovation

Retrieved on: 
Tuesday, February 27, 2024

"I joined Rival just over a year ago to challenge the status quo in HR technology and transform the product suite into the most advanced offering on the market,” said Rival Chief Product Officer Poornima Farrar.

Key Points: 
  • "I joined Rival just over a year ago to challenge the status quo in HR technology and transform the product suite into the most advanced offering on the market,” said Rival Chief Product Officer Poornima Farrar.
  • “These patents represent not only my but the entire company's passion for innovation and our dedication to enhancing all aspects of Talent Acquisition.
  • “SilkRoad completely disrupted the HR technology space with the launch of RedCarpet Onboarding and these patents are evidence that we will continue to lead the market in innovation as Rival,” said Rival CEO Greg DiTullio.
  • “We are drawing on our rich heritage to identify the most important pain points for Talent Acquisition and all HR practitioners to address with bleeding-edge technology.

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Monday, February 26, 2024

(the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.

Key Points: 
  • (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.
  • Financial results for the quarter ended December 31, 2023:
    Cash, cash equivalents, and investments totaled $594.1 million on December 31, 2023.
  • The Company recorded net product revenue of $42.1 million from sales of VYJUVEK during the quarter ended December 31, 2023.
  • For additional information on the Company’s financial results for the year ended December 31, 2023, please refer to the Form 10-K filed with the Securities and Exchange Commission.

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Retrieved on: 
Monday, February 26, 2024

PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH).

Key Points: 
  • PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW ) (“LIXTE” or the “Company”) today announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH).
  • The scope of this clinical research extends to checkpoint inhibitors, immunotherapy, and radiation for the treatment of cancer.
  • The agreement reinforces our dedication to pioneering research and delivering innovative solutions to patients battling cancer," he added.
  • The licensed patent rights provide LIXTE with a unique opportunity to explore and develop novel combination therapies that can potentially transform the landscape of cancer treatment.

Applied Optoelectronics Filed Patent Infringement Lawsuit Against CIG

Retrieved on: 
Thursday, February 22, 2024

The complaint, filed February 20, 2024, in the U.S. District Court for the Northern District of California, alleges that at least the CIG 100G QSFP28 CWDM4 Module Version 1, the CIG 100G QSFP28 CWDM4 Module Version 2, the CIG 100G LR4 Module, the CIG 400G QSFP-DD DR4 Module, the CIG 400G QSFP-DD FR4 Module, and the CIG 100G QSFP28 PSM4 optical transceiver module infringe one or more of the eight asserted of Applied Optoelectronic, Inc. (AOI) optical transceiver patents.

Key Points: 
  • The complaint, filed February 20, 2024, in the U.S. District Court for the Northern District of California, alleges that at least the CIG 100G QSFP28 CWDM4 Module Version 1, the CIG 100G QSFP28 CWDM4 Module Version 2, the CIG 100G LR4 Module, the CIG 400G QSFP-DD DR4 Module, the CIG 400G QSFP-DD FR4 Module, and the CIG 100G QSFP28 PSM4 optical transceiver module infringe one or more of the eight asserted of Applied Optoelectronic, Inc. (AOI) optical transceiver patents.
  • “This lawsuit against CIG is a necessary step to protect AOI’s intellectual property that has been obtained through research and development, innovation, and investment.
  • AOI will vigorously enforce its IP rights against alleged infringers,” said Dr. Thompson Lin, Applied Optoelectronics, Inc.
  • In the complaint, AOI is seeking monetary damages from CIG and a permanent injunction.

Healthcare Integrated Technologies, Inc. Announces Issuance of Second U.S. Patent for Innovative Transaction Validation System

Retrieved on: 
Thursday, February 22, 2024

Knoxville, Tennessee, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Healthcare Integrated Technologies, Inc. (“HiTC”), a leading innovator of healthcare technology solutions, is proud to announce the issuance of its second United States patent number 11,866,950, on January 30, 2024.

Key Points: 
  • Knoxville, Tennessee, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Healthcare Integrated Technologies, Inc. (“HiTC”), a leading innovator of healthcare technology solutions, is proud to announce the issuance of its second United States patent number 11,866,950, on January 30, 2024.
  • The patent is titled "System and Method for Assessing and Verifying the Validity of a Transaction."
  • The patent underscores HiTC’s commitment to pioneering solutions for transaction verification and compliance monitoring across various industries.
  • This groundbreaking technology offers a robust framework for validating transactions through an intricate system of sensors and artificial intelligence (AI).

Mass Megawatts Announces Several New Product Lines with Lowest and Competitive Prices as a Source of Generating Revenue

Retrieved on: 
Thursday, February 22, 2024

We sell and supply the top brands when it comes to solar equipment from solar panels, racking, inverters, wiring, and more.

Key Points: 
  • We sell and supply the top brands when it comes to solar equipment from solar panels, racking, inverters, wiring, and more.
  • We can also supply equipment for both generating and storing your own power at the best prices available.
  • Our products are sourced from top manufacturers, ensuring that you receive reliable and long-lasting equipment for your solar energy needs.
  • Unlike other solar tracking technologies, the Mass Megawatts Solar Tracker utilizes a low-cost framework that adds stability to the overall system, while improving energy production levels.

Save Foods: NTwo Off Filed US Patent Application to Reduce Greenhouse Gas Emissions in Wheat Production

Retrieved on: 
Thursday, February 22, 2024

The patent application represents NTwo Off’s goal to assist in mitigating the environmental impact of agriculture, specifically targeting the reduction of nitrous oxide (N2O) emissions in wheat farming.

Key Points: 
  • The patent application represents NTwo Off’s goal to assist in mitigating the environmental impact of agriculture, specifically targeting the reduction of nitrous oxide (N2O) emissions in wheat farming.
  • The patented technology refers to methodologies of effectively mitigating nitrous oxide emissions during wheat cultivation.
  • By implementing this innovative approach, NTwo Off hopes to reduce farmers' environmental footprint while enhancing their sustainability of operations.
  • NTwo Off has identified and isolated two naturally occurring bacteria species that can reduce N2O emissions under various environmental conditions from wheat roots.

RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy

Retrieved on: 
Thursday, February 22, 2024

PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“ RetinalGeniX ” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy.

Key Points: 
  • PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“ RetinalGeniX ” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy.
  • The present invention relates to systems and methods for visualizing eye anatomy for diagnostic and therapeutic purposes.
  • Furthermore, it allows for the detection and analysis of various conditions of the eye, such as, hydration, innervations, inflammation, circulation, nerve conduction, etc.
  • Some of the best-studied ocular conformational diseases include cataracts in the lens and retinitis pigmentosa in the retina.

Mexican Rail Operator Renews Support Contract and Adds Duos AI

Retrieved on: 
Thursday, February 22, 2024

Additionally, the agreement includes the renewal of their annual services and maintenance contract, which now encompasses expanded support through Duos' Preventative Maintenance Checks and Services (PMCS) Program and Field Services Support, aimed at further improving the performance of the rail network.

Key Points: 
  • Additionally, the agreement includes the renewal of their annual services and maintenance contract, which now encompasses expanded support through Duos' Preventative Maintenance Checks and Services (PMCS) Program and Field Services Support, aimed at further improving the performance of the rail network.
  • The renewal agreement includes an annual subscription for an array of AI algorithms requested by the client who uses the Duos patented Railcar Inspection Portal ( RIP® ) and AI to quickly and efficiently detect critical issues that could potentially lead to accidents or derailments.
  • Our patented Railcar Inspection Portal and AI are now being used by four of the large freight rail carriers in North America.
  • Duos was recently awarded a Patent for this AI technology underscoring the high performance of Duos’ AI offerings which have been developed using rail industry experts.